Neuropharmacology of Cannabinoids: A Comprehensive Review of Preclinical and Clinical Evidence for Hemp-Derived Extracts and Active Compounds. (PubMed, Pharmaceuticals (Basel)) - Aug 28, 2026 - "Moderate-certainty evidence supports nabiximols for multiple sclerosis spasticity and small benefits in selected chronic neuropathic pain populations...Key risks include cannabis use disorder, cognitive and psychiatric effects, cardiovascular events, sedation, high-dose CBD hepatotoxicity, and drug interactions. Rigorous, long-term, product-standardized trials are needed."
Journal • Preclinical • Review • Alzheimer's Disease • Anesthesia • Anorexia • Cardiovascular • Chemotherapy-Induced Nausea and Vomiting • CNS Disorders • Cognitive Disorders • Epilepsy • Human Immunodeficiency Virus • Huntington's Disease • Infectious Disease • Insomnia • Mental Retardation • Movement Disorders • Multiple Sclerosis • Neuralgia • Pain • Parkinson's Disease • Psychiatry • Sleep Disorder • Substance Abuse • GPR55 • PPARG
|
|
Alaa Abd-Elsayed; Charles A Odonkor; David A Karpe; Muhammad Uzair Siddique
|